Reneo Pharmaceuticals, Inc.

As of June 2, 2025, Reneo Pharmaceuticals, Inc. shows a mildly bearish trend with mixed signals, including a bearish daily moving average and a bearish monthly Dow Theory stance, suggesting caution in the current market environment.

Reneo Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $16 million and a market cap of $30.62 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -66.39%.

As of Jun 18, Reneo Pharmaceuticals, Inc. has a market capitalization of 30.62 million, with net sales of 0.00 million and a net profit of -60.17 million for the latest four quarters. As of December 2024, the company reported shareholder's funds of 103.83 million and total assets of 114.91 million.